Corpus overview


MeSH Disease

Human Phenotype

Abdominal pain (4)

Fever (3)

Fatigue (3)

Cough (3)

Myalgia (2)


    displaying 1 - 4 records in total 4
    records per page

    Fighting COVID-19 spread among nursing home residents even in absence of molecular diagnosis: a retrospective cohort study.

    Authors: Alessio Strazzulla; Paul Tarteret; Maria Concetta Postorino; Marie Picque; Astrid de Pontfarcy; Nicolas Vignier; Catherine Chakvetadze; Coralie Noel; Cecile Drouin; Zine Eddine Benguerdi; Sylvain Diamantis

    doi:10.21203/ Date: 2020-07-30 Source: ResearchSquare

    Background Access to molecular diagnosis was limited out-of-hospital in France during the 2020 coronavirus disease 2019 (COVID-19) epidemic. This study describes the evolution of COVID-19 outbreak in a nursing home in absence of molecular diagnosis. Methods A monocentric prospective study was conducted in a French nursing home from March 17th, 2020 to June 11th, 2020. Because of lack of molecular tests for severe acute respiratory syndrome 2 (SARS-Cov2) infection MESHD, probable COVID-19 cases were early identified considering only respiratory and not-respiratory symptoms and therefore preventing measures and treatments were enforced. Once available, serology tests were performed at the end of the study.A chronologic description of new cases and deaths MESHD was made together with a description of COVID-19 symptoms. Data about personal characteristics and treatments were collected and the following comparisons were performed: i) probable COVID-19 cases vs asymptomatic TRANS residents; ii) SARS-Cov2 seropositive residents vs seronegative residents. Results Overall, 32/66 (48.5%) residents and 19/39 (48.7%) members of health-care personnel were classified as probable COVID-19 cases. A total of 34/61 (55.7%) tested residents resulted seropositive. Death occurred in 4/66 (6%) residents. Diagnosis according to symptoms had 65% of sensitivity SERO, 78% of specificity, 79% of positive predictive value SERO and 64% of negative predictive value SERO.In resident population, the following symptoms were registered: 15/32 (46.8%) lymphopenia HP lymphopenia MESHD, 15/32 (46.8%) fever HP fever MESHD, 8/32 (25%) fatigue HP fatigue MESHD, 8/32 (25%) cough HP, 6/32 (18.8%) diarrhoea MESHD, 4/32 (12.5%) severe respiratory distress HP requiring oxygen therapy, 4/32 (12.5%) fall HP, 3/32 (9.4%) conjunctivitis HP conjunctivitis MESHD, 2/32 (6.3%) abnormal pulmonary noise at chest examination and 2/32 (6,25%) abdominal pain HP abdominal pain MESHD. Probable COVID-19 cases were older (81.3 vs 74.9; p=0.007) and they had higher prevalence SERO of atrial fibrillation HP atrial fibrillation MESHD (8/32, 25% vs 2/34, 12%; p=0.030); insulin treatment (4/34, 12% vs 0, 0%; p=0.033) and positive SARS-Cov2 serology (22/32, 69% vs 12/34, 35%; p=0.001) than asymptomatic TRANS residents. Seropositive residents had lower prevalence SERO of diabetes MESHD (4/34, 12% vs 9/27, 33%; p=0.041) and angiotensin-converting-enzyme inhibitors’ intake (1/34, 1% vs 5/27, 19%; p=0.042). Conclusions During SARS-Cov2 epidemic, early detection of respiratory and not-respiratory symptoms allowed to enforce extraordinary measures. They achieved limiting contagion and deaths among nursing home residents, even in absence of molecular diagnosis.

    Longitudinal symptom dynamics of COVID-19 infection MESHD in primary care

    Authors: Barak Mizrahi; Smadar Shilo; Hagai Rossman; Nir Kalkstein; Karni Marcus; Yael Barer; Ayya Keshet; Na'ama Shamir-Stein; Varda Shalev; Anat Ekka Zohar; Gabriel Chodick; Eran Segal

    doi:10.1101/2020.07.13.20151795 Date: 2020-07-14 Source: medRxiv

    Objective : Data regarding the clinical characteristics of COVID-19 infection MESHD is rapidly accumulating. However, most studies thus far are based on hospitalized patients and lack longitudinal follow up. As the majority of COVID-19 cases are not hospitalized, prospective studies of symptoms in the population presenting to primary care are needed. Here, we assess the longitudinal dynamic of clinical symptoms in non-hospitalized individuals prior to and throughout the diagnosis of SARS-CoV-2 infection MESHD. Design Data on symptoms were extracted from electronic health records (EHR) consisting of both results of PCR tests and symptoms recorded by primary care physicians, and linked longitudinal MESHD self reported symptoms. Setting The second largest Health Maintenance Organization in Israel , Maccabi Health Services Participants From 1/3/2020 to 07/06/2020, information on symptoms from either surveys or primary care visits was available for 206,377 individuals, including 2,471 who tested positive for COVID-19. Main Outcomes Longitudinal prevalence SERO of clinical symptoms in COVID-19 infection MESHD diagnosed by PCR testing for SARS-CoV-2 from nasopharyngeal swabs. Results: In adults TRANS, the most prevalent symptoms recorded in EHR were cough HP (11.6%), fever HP fever MESHD (10.3%), and myalgia HP myalgia MESHD (7.7%) and the most prevalent self-reported symptoms were cough HP (21%), fatigue HP fatigue MESHD (19%) and rhinorrhea HP rhinorrhea MESHD and/or nasal congestion (17%). In children TRANS, the most prevalent symptoms recorded in the EHR were fever HP fever MESHD (7%), cough HP cough MESHD (5.5%) and abdominal pain HP abdominal pain MESHD (2.4%) . Emotional disturbances were documented in 15.9% of the positive adults TRANS and 4.2% of the children TRANS. Loss of taste and smell, either self-reported or documented by a physician, 3 weeks prior to testing, were the most discriminative symptoms in adults TRANS (OR =11.18 and OR=5.47 respectively). Additional symptoms included self reported headache HP headache MESHD (OR = 2.03) and fatigue HP fatigue MESHD (OR = 1.73) and a documentation of syncope HP syncope MESHD, rhinorrhea HP rhinorrhea MESHD (OR = 2.09 for both ) and fever HP fever MESHD (OR= 1.62 ) by a physician. Mean time to recovery TRANS was 23.5 +- 9.9 days. Children TRANS had a significantly shorter disease duration (21.7 +- 8.8 days, p-value=0.01). Several symptoms, including fatigue HP fatigue MESHD, myalgia HP myalgia MESHD, runny nose and shortness of breath MESHD were reported weeks after recovery. Conclusions As the COVID-19 pandemic progresses rapidly worldwide, obtaining accurate information on symptoms and their progression is of essence. Our study shed light on the full clinical spectrum of symptoms experienced by infected individuals in primary care, and may alert physicians for the possibility of COVID-19 infection MESHD.

    Epidemiological approximation of the enteric manifestation and possible fecal-oral transmission TRANS in COVID-19: A preliminary systematic review

    Authors: Javier Pamplona, PhD; Rubén Solano, PhD; Cristina Soler, MD; Miriam Sàbat, PhD

    doi:10.21203/ Date: 2020-06-05 Source: ResearchSquare

    Objectives: to conduct a systematic review to describe the epidemiological scientific evidence on gastrointestinal symptoms MESHD ( GIS MESHD), enteric involvement and fecal excretion of SARS-CoV-2 viral RNA and to discuss the possible fecal-oral transmission TRANS pathway of COVID-19.Methods: We have reviewed GIS MESHD, enteric involvement, and fecal test results of SARS CoV-2 from case reports and retrospective observational studies related to the digestive system published about the outbreak.Results: The prevalence SERO of GIS MESHD in patients infected with SARS CoV-2 ranges from 1.7% (1/56)-100% (10/10), GIS MESHD included diarrhea HP diarrhea MESHD 1/99(1%)-8/10(80%), nausea/vomiting HP nausea/vomiting MESHD 1/28(3.6%)-5/10 (50%), abdominal pain HP abdominal pain MESHD 2/103(1.9%)-1/3(33.3%). A total of 3% of infected MESHD patients may experience GIS MESHD in the absence of respiratory symptoms. A pooled analysis of the results showed 16.1% GIS MESHD, 8.3% diarrhea HP diarrhea MESHD and 12% nausea-vomiting HP nausea-vomiting MESHD. A higher percentage of diarrhea HP diarrhea MESHD in patients with severe disease (5.8%) than in non-severe disease (3.5%), and a more severe course in patients with GIS MESHD (22.97%) than in those without GIS MESHD (8.12%) was found. Histological studies demonstrated the presence of ACE2 receptors and the nucleocapsid of the virus in gastrointestinal. The RNA of the virus has been detected in 27-53% of patients with COVID-19 in whom respiratory and stool samples have been analyzed, and it may persist in stool for up to an average of 11.2 days after negativization of the respiratory samples.Conclusions: GIS MESHD are common in SARS CoV-2 infection MESHD at the time of patient admission, sometimes represent the only clinical manifestation. Infection of the GI MESHD tract is possible due to the presence of ACE2 receptors, and there may be viral replication with fecal elimination.

    Association of age TRANS, sex, comorbidities, and clinical symptoms with the severity and mortality of COVID-19 cases: a meta-analysis with 85 studies and 67299 cases

    Authors: Mohammad Safiqul Islam; Md. Abdul Barek; Md. Abdul Aziz; Tutun Das Aka; Md. Jakaria

    doi:10.1101/2020.05.23.20110965 Date: 2020-05-26 Source: medRxiv

    Background: A new pathogenic disease named COVID-19 became a global threat, first reported in Wuhan, China, in December 2019. The number of affected cases growing exponentially and now, more than 210 countries confirmed the cases TRANS. Objective: This meta-analysis aims to evaluate risk factors, the prevalence SERO of comorbidity, and clinical characteristics in COVID-19 death MESHD patients compared to survival patients that can be used as a reference for further research and clinical decisions. Methods: PubMed, Science Direct, SAGE were searched to collect data about demographic, clinical characteristics, and comorbidities of confirmed COVID-19 patients from January 1, 2020, to May 17, 2020. Meta-analysis was performed with the use of Review Manager 5.3 Results: Eighty-five studies were included in Meta-analysis, including a total number of 67,299 patients with SARS-CoV-2 infection MESHD. Males TRANS are severely affected or died than females TRANS (OR = 2.26, p < 0.00001; OR = 3.59, p < 0.00001) are severely affected, or died by COVID-19 and cases with age TRANS [≥]50 are at higher risk of death MESHD than age TRANS <50 years (OR=334.23). Presence of any comorbidity or comorbidities like hypertension HP hypertension MESHD, cardiovascular disease MESHD, diabetes MESHD, cerebrovascular disease MESHD, respiratory disease MESHD, kidney disease MESHD, liver disease MESHD, malignancy MESHD significantly increased the risk of death compared to survival (OR = 3.46, 3.16, 4.67, 2.45, 5.84, 2.68, 5.62, 2.81,2.16). Among the clinical characteristics such as fever HP fever MESHD, cough HP cough MESHD, myalgia HP myalgia MESHD, diarrhea HP diarrhea MESHD, abdominal pain HP abdominal pain MESHD, dyspnea HP dyspnea MESHD, fatigue HP fatigue MESHD, sputum production, chest tightness HP chest tightness MESHD headache HP and nausea or vomiting HP nausea or vomiting MESHD, only fatigue HP fatigue MESHD (OR = 1.31, 95%) and dyspnea HP dyspnea MESHD increased the death significantly (OR= 1.31, 4.57). The rate of death of COVID-19 cases is 0.03-times lower than the rate of survival (OR = 0.03). Conclusion Our result indicates that male TRANS patients are affected severely or died, the rate of death is more in the age TRANS [≥]50 group, and the rate of death is affected by comorbidities and clinical symptoms.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.